All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.
During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke to Bruno Paiva, University of Navarra, Pamplona, ES, about the importance of monitoring measurable residual disease (MRD) status.
How should we monitor risk of progression in patients achieving MRD negativity after auto-SCT?
We asked, How should we monitor risk of progression in patients achieving MRD negativity after autologous stem cell transplant?
Your opinion matters
Efficacy of autologous stem cell transplantation in patients aged ≥ 70 years with multiple myeloma
The impact of older age at transplant and its effect on post-transplant outcomes
High sensitivity of mass spectrometry based M-protein detection
This MS test to measure serum M-proteins has improved sensitivity over other methods and could enable meaningful tracking of disese progression over time.
Subscribe to get the best content related to multiple myeloma delivered to your inbox